- 专利标题： COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS
-
申请号： US17781699申请日： 2020-12-02
-
公开(公告)号： US20230029259A1公开(公告)日： 2023-01-26
- 发明人: Yifan Zhai , Dajun Yang , Douglas Dong Fang , Qiang Li
- 申请人： Ascentage Pharma (Suzhou) Co., Ltd. , Ascentage Pharma Group Corp Limited
- 申请人地址： CN Suzhou; CN Hong Kong
- 专利权人： Ascentage Pharma (Suzhou) Co., Ltd.,Ascentage Pharma Group Corp Limited
- 当前专利权人： Ascentage Pharma (Suzhou) Co., Ltd.,Ascentage Pharma Group Corp Limited
- 当前专利权人地址： CN Suzhou; CN Hong Kong
- 优先权： CNPCT/CN2019/122402 20191202,CN202011295946.7 20201118
- 国际申请： PCT/CN2020/133246 WO 20201202
- 主分类号： C07D519/00
- IPC分类号： C07D519/00 ; A61P35/00
摘要：
A pharmaceutical composition comprising: a) an effective amount of an Inhibitors of Apoptosis Proteins (IAP) inhibitor, wherein the IAP inhibitor is represented by formula (I): or a pharmaceutically acceptable salt thereof, the definitions of each variable are provided herein; b) an effective amount of a second inhibitor, wherein the second inhibitor is a poly ADP ribose polymerase (PARP) inhibitor or a mitogen-activated protein kinase kinase (MEK) inhibitor; and a pharmaceutically acceptable carrier or diluent.
信息查询
